Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Asia Pacific ImmunoOncology Research & Development

BeiGene Is Keeping The Faith In IO/IO Combinations

Part 2 of 2

  • Interviews

Executive Summary

Global head of R&D Lai Wang talked to Scrip about his expectations for a PD-1/TIGIT combination and remaining confident about the potential of IO/IO combinations in cancer despite disappointments. 

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: new data for Factor XIa inhibitors; Farxiga in heart failure; Lumakras succeeds in lung cancer; MSD’s India head on company plans; and BeiGene’s confidence in IO/IO combinations.

BeiGene Head of R&D Lai Wang On Going Global

The Chinese company's R&D leader talked to Scrip about the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.

Roche Is ‘Aiming For The Sky’ With Vabysmo Commercial Launch

CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.

Table

View full table

Related Content

Scrip
Scrip
Pink Sheet
Scrip
Scrip

Topics

Related Companies

Tags:
Asia Pacific ImmunoOncology Research & Development
Latest News

Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials

AstraZeneca Pulls Plug On Ionis’ PCSK9 Candidate

Biogen Prepares More Doubtful Phase III Results For FDA Scrutiny, This Time In ALS

Leqvio Launch Will Be Fundamental To Success Of New Novartis

See All
UsernamePublicRestriction

Register

SC146949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By